Posted by Michael Wonder on 05 May 2022
Health Canada approves Ipsen's Cabometyx (cabozantinib) for patients with previously treated radioactive iodine refractory or ineligible differentiated thyroid cancer
Pivotal Phase 3 trial data showed Cabometyx demonstrated a significant improvement in progression-free survival.
Ipsen Biopharmaceuticals Canada today announced the Health Canada approval of Cabometyx (cabozantinib) for the treatment of adults with locally advanced or metastatic differentiated thyroid carcinoma that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine refractory or ineligible.
Cabometyx was granted priority review for differentiated thyroid carcinoma by Health Canada because of the significant unmet need it fills for this patient population.
